Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1999-6-9
pubmed:abstractText
1. C335Stop is a constitutively active mutant of the TRH receptor (TRH-R). To investigate the mechanism of the decreased responsiveness of C335Stop TRH-R, we studied cellular Ca2+ concentrations ([Ca2+]i) in AtT20 cells stably transfected with C335Stop TRH-R cDNA, or Ca2+-activated chloride currents in Xenopus laevis oocytes expressing this mutant receptor after injection of cRNA. The competitive TRH-R binding antagonist, chlorodiazepoxide (CDE), was used as an inverse agonist to study the contribution of constitutive activity to desensitization. 2. Acute treatment with CDE resulted in a rapid (within minutes) decrease in [Ca2+]i and an increase in the response amplitude to TRH with no measurable change in receptor density. Conversely, removal of chronically administered CDE caused a rapid increase in [Ca2+]i and a decrease in TRH response amplitude. 3. CDE abolished heterologous desensitization induced by C335Stop TRH-R on muscarinic m1-receptor (ml-R) co-expressed in Xenopus oocytes. 4. Chelation of extracellular calcium with EGTA caused a rapid decrease in [Ca2+]i and a concomitant increase in the response to TRH in AtT20 cells expressing C335Stop TRH-Rs. 5. Chelerythrine, a specific inhibitor of protein kinase C (PKC), reversed the heterologous desensitization of the response to acetylcholine (ACh). The phosphoserine/phosphothreonine phosphatase inhibitor, okadaic acid, abolished the effect of chelerythrine. 6. Down-regulation of PKC by chronic exposure to phorbol 12-myristate 13-acetate (PMA) or acute inhibition with chelerythrine caused a partial resensitization of the response to TRH. 7. Western analysis indicated that the alpha subtype of protein kinase C was down-regulated in cells expressing C335Stop TRH-Rs. Following a 5 min exposure to PMA, the residual alphaPKC translocated to the particular fraction. 8. We propose that cells expressing the constitutively active mutant TRH-R rapidly desensitize their response, utilizing a mechanism mediated by an increase in [Ca2+]i and PKC.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-1346134, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-1851762, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-2159409, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-2168222, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-2175902, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-2472599, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-2540197, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-3015558, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-3838314, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7472500, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7525564, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7526863, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7529770, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7539127, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7559644, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7578017, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7670732, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7692306, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7781920, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7812608, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7836357, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-7908404, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-8095262, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-8393865, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-8413622, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-8458074, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-8531139, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-8567630, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-8584022, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-8604989, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-8643081, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-8990958, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-9075704, http://linkedlifedata.com/resource/pubmed/commentcorrection/10204996-9607146
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
126
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1097-106
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Inverse agonist abolishes desensitization of a constitutively active mutant of thyrotropin-releasing hormone receptor: role of cellular calcium and protein kinase C.
pubmed:affiliation
Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't